SAN DIEGO, Oct. 14, 2025 /PRNewswire/ -- Cortechs.ai, a leader in AI-driven neuroimaging software, today announces the acquisition of intellectual property from ZepMed, LLC, including its patented CT imaging technologies and flagship product, NeuroAlign CT™. This strategic acquisition strengthens Cortechs.ai's position at the forefront of radiological innovation and expands its suite of best-in-class solutions for clinicians worldwide.
"With this acquisition, we're not just expanding our portfolio, we're building on ZepMed's foundation to elevate development and deliver even more powerful tools to our users," said Kyle Frye, CEO of Cortechs.ai. "This is an exciting growth milestone as we continue to enhance the solutions trusted by healthcare professionals around the globe."
ZepMed, renowned for its pioneering work in CT imaging, developed NeuroAlign CT™, a Class II FDA-cleared software that automates segmentation, alignment, and reformatting of head CT scans. The technology enhances diagnostic accuracy and streamlines radiology workflows, empowering clinicians to detect subtle changes in brain anatomy with greater confidence and speed.
Ad Statistics
Times Displayed: 6679
Times Visited: 20 Brand-New FDA-cleared Advanced Ultrasound Medical Device available for sale or lease to Wound Care Centers or any other Medical Facilities.The Arobella 1000D is designed for non-contact or debridement ultrasound wound healing therapy, or any other wounds
"We at ZepMed are proud of what we built with NeuroAlign®, and we are excited to see it reach its full potential in the hands of Cortechs.ai," said Douglas Bates, MD, co-founder of ZepMed. "Cortechs' support and development team will enhance user experience and add features, ensuring that the technology benefits more clinicians and patients worldwide."
"This ownership strengthens our commitment to delivering AI-powered diagnostic solutions that span both neuroimaging and radiology," said Daniel Livschutz, Chairman of the Board for Cortechs.ai and Founding Partner of VILAS Ventures. "As investors, we're proud to support Cortechs.ai's record growth, IP ownership and strategic expansion as market leaders. With the integration of ZepMed's innovations, we're not just adding capabilities, we're architecting a continuum of care that spans surveillance, diagnosis, and risk. This positions Cortechs to complete the entire precision medicine value chain, moving beyond silos toward a multimodal ecosystem that better serves patients, clinicians, and payers alike. We're excited to continue building the Cortechs.ai platform and look forward to the impact it will drive worldwide."
By bringing ZepMed's technology under its ownership, Cortechs.ai accelerates innovation and broadens its neuroimaging portfolio, reinforcing its leadership in AI-powered radiology and its mission to improve patient outcomes through precision diagnostics.
